San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type-1 diabetes, hepatitis, ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotechnology company Capstan Therapeutics, Inc., in a bid to boost its ...

NORTH CHICAGO, IL and SAN DIEGO, CA, USA I June 30, 2025 I AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

Examples of specific types of immunotherapies include dendritic cell therapy (sipuleucel-T), adoptive T-cell therapy (CAR-T), antibody therapy (anti-CD47, anti-GD2, anti-CD52, anti-PD-L1, anti-SLAMF7, ...

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative ...

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.